Skip to main content
Home
Home

王紫 Viola T. Kung

Profile photo for Viola T. Kung
Profile photo for Viola T. Kung
合伙人

王紫 Viola T. Kung

Viola 专精于化学、制药、诊断学、生物技术和小分子领域的专利申请与咨询。

作为一名经验丰富的发明家,Viola Kung 协助化学、制药和生物技术领域的客户处理专利事务。她在美国专利商标局的专利申请、复审和上诉程序方面经验丰富。Viola 的其他咨询经验包括意见书,自由操作权,有效性和尽职调查评估。

Viola 的执业领域涵盖多个行业和产品,包括癌症治疗、炎症性疾病、眼科疾病、神经系统疾病、神经精神疾病、肺部疾病、自身免疫性疾病和疼痛的治疗方法。她还参与了以下领域相关事务:免疫疗法、CAR-T 细胞疗法、检查点抑制剂、药物制剂、新化学实体、化学过程、医疗器械、体外诊断、下一代测序、基因表达、肿瘤抑制基因、融合蛋白、CRISPR/Cas9 基因编辑技术和碳纳米管。

Viola 是一名受过良好职业训练的科学家,拥有超过 15 年研发工作经验。在大量的科学研究中,作为研发总监与研究科学家,Viola 在药物制剂、检测开发、体外诊断、蛋白质和 DNA 相互作用、双层脂膜、偶联化学和分子生物学方面积累了大量的研发经验。

Viola 是 21 项美国专利的发明人,专利涉及领域包括:免疫测定、偶联化学、脂质体制剂、DNA 检测方法和医疗设备。此外,Viola 还在许多科学期刊中发表过大量论文。

教育与证书

教育

  • Santa Clara University School of Law, J.D., 2000
  • 加州大学伯克利分校, Ph.D., 化学/生物化学, 1978
  • 国立台湾大学, 化学学士, 1974

律师和法庭资格

  • California
  • U.S. Patent and Trademark Office
  • 美国加利福尼亚州北区联邦地区法院

相关工作经历

  • 美国豪锐律师事务所(Howrey),帕罗奥多,加州,合伙人,知识产权业务部
  • Rae-Venter Law Group,帕罗奥多,加州,专利代理人,知识产权业务部
  • Metra Biosystems, Inc. , 研发总监
  • Molecular Devices Corp.,高级科学家
  • Liposome Technology, Inc.,高级科学家
  • International Immunoassay Laboratories,研究员

专业认可

  • 入选《钱伯斯美国》生命科学、知识产权/专利诉讼领域“美国领先律师 ”,2016-2023

  • 获 《 IAM 全球专利 1000 强》( IAM Patent 1000 )推荐 ,2016-2024

  • 荣膺 2023 年《Patexia 专利情报》“最佳表现律师”之一

  • 被《美国最佳律师》 ( The Best Lawyers in America ) 评为专利法领域最佳律师, 2016-2023

  • 入选《知识产权管理》( Managing IP )“ IP 之星 ”,2013-2014, 2016-2024

  • 入选《知识产权管理》( Managing IP )“ 250 名 IP 女性精英 ”,2013,2014

  • 被《 Daily Journal 》评为 “ 最优秀的 25 名知识产权组合管理者 ” 之一, 2010,2012

影响

专业领导力

  • 美国律师协会,成员

代理经验

Experience

U.S. Patent 11,725,053

The invention is directed to a chimeric antigen receptor (CAR) fusion protein comprising: (1) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against a tumor antigen, (2) a transmembrane domain, (3) at least one co-stimulatory domain, and (4) an activating domain; wherein the CAR further comprises a human transferrin fragment, at N-terminus or C-terminus to scFv, or between VH and VL. Preferred tumor antigens are CD19, CD22 and BCMA.

U.S. Patent 11,572,353

The invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, as shown in general formula (I) and a pharmaceutically acceptable salt thereof. The invention also relates to a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound, and a preparation method for the compound.

U.S. Patent 11,517,554

The invention is directed to a method for preventing and/or treating Alzheimer's disease. The method comprises administering to a subject in need thereof an effective amount of dapansutrile. The method reduces neuroinflammation and improves the cognitive functions such as learning and memory processes of the subject.

U.S. Patent 11,345,695

Compounds of Formula I and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases—including cancer, inflammation, and autoimmune disease—mediated at least in part by Bruton's Tyrosine Kinase (BTK). 

U.S. Patent 11,173,064

The present invention relates to a nanocomposite ocular device that can release drugs within a close distance to the ocular surface and provide controlled and sustained release of the drug at a constant rate. The device comprises a drug, one or more reservoir domains, and a barrier layer configured to block the drug diffusion paths from the reservoir domain to the ocular surface in the eye of the subject.

U.S. Patent 11,149,075

Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially nonaggregating and suitable for therapeutic, diagnostic, and/or research applications.

U.S. Patent 11,046,748

The present invention relates to chimeric antigen receptors (CARs) specific to ICAM-1, comprising I domain of the αL subunit of human lymphocyte function-associated antigen 1 (LFA-1). CAR T cells comprising human I domain having a low affinity to ICAM-1 can avoid targeting healthy tissues with basal ICAM-1 expression while exhibiting increased potency and long-term efficacy against tumor tissues with high ICAM-1 expression.

U.S. Patent 10,840,032

The present invention is directed to a supercapacitor cell having at least one electrode comprising a current collector and an active layer, wherein the active layer comprises activated carbon and high purity carbon nanotubes and is free of binder. The content of carbon nanotubes in the active layer is between 10 and 30 wt%, and the purity of the carbon nanotubes is at least 95 wt%.

U.S. Patent 10,718,764

The present invention is directed to a luminescent immunoassay method for detecting an analyte in a liquid sample with high sensitivity. The invention provides a unique combination of (1) using a probe having a small sensing surface area for binding analyte molecules, (2) using a high molecular weight polymer conjugated with multiple binding molecules and luminescent labels, and (3) cycling the probe having immunocomplex formed and repeating the reaction to improve the sensitivity of detection level.

U.S. Patent 10,654,911

The invention relates to a co-expression vector that comprises both truncated von Williebrand Factor (vWF)-Fc DNA construct and B-domain deleted FVIII DNA construct in the same vector. By co-expressing FVIII and truncated vWF-Fc with one expression vector in cells, the present invention controls the ratio of gene templates for FVIII and vWF proteins, and creates a higher yield and more stable expression of FVIII protein molecules. 

U.S. Patent 10,221,448

The invention relates to a scalable multiplex PCR method that can simultaneously amplify overlapping amplicons without the drawbacks of conventional multiplex PCR. The method selectively amplifies target nucleic acid fragments having an overlapping region.

U.S. Patent 9,745,382

The present invention relates to humanized bispecific anti-HER2 antibodies that comprise one antigen binding site containing variable regions of heavy and light chain of trastuzumab, and another antigen binding site containing variable regions of heavy and light chains of pertuzumab. The bispecific anti-HER2 antibodies are effective for treating cancer.

Home
Jump back to top